Carnegie Mellon and Yale Study in Mice Shows Promise for Treating Genetic Conditions During Early Stages of Development
Researchers at Carnegie Mellon University and Yale University have for the first time used a gene editing technique to successfully cure a genetic condition in utero in a mouse model. Their findings, published in Nature Communications, present a promising new avenue for research into treating genetic conditions during fetal development.
An estimated 8 million children are born each year with severe genetic disorders or birth defects. Genetic conditions can often be detected during pregnancy using amniocentesis, but there are no treatment options to correct these genetic conditions before birth.
“Early in embryonic development, there are a lot of stem cells dividing at a rapid pace. If we can go in and correct a genetic mutation early on, we could dramatically reduce the impact the mutation has on fetal development or even cure the condition,” said Danith Ly, professor of chemistry in Carnegie Mellon’s Mellon College of Science.
In this study, the researchers used a peptide nucleic acid-based gene editing technique that they had previously used to cure beta thalassemia, a genetic blood disorder that results in the reduced production of hemoglobin, in adult mice.
Peptide nucleic acids are synthetic molecules that combine a synthetic protein backbone with the nucleobases found in DNA and RNA. The PNAs used in this study were created by Ly at Carnegie Mellon’s Center for Nucleic Acids Science and Technology (CNAST), a leading center for PNA science.
Their technique uses an FDA-approved nanoparticle to deliver PNA molecules paired with donor DNA to the site of a genetic mutation. When the PNA-DNA complex identifies a designated mutation, the PNA molecule binds to the DNA and unzips its two strands. The donor DNA binds with the faulty DNA and spurs the cell’s DNA repair pathways into action, allowing it to correct the error.
In the current study, the researchers used a technique similar to amniocentesis to inject the PNA complex into the amniotic fluid of pregnant mice whose fetuses carried a mutation in the beta-globin gene that causes beta thalassemia.
With just one injection of the PNA during gestation, the researchers were able to correct 6 percent of the mutations. This 6 percent correction was enough to cause dramatic improvements in the mice’s symptoms of beta thalassemia – and enough for the mice to be considered cured. Mice that were treated using PNA while in utero had levels of hemoglobin that were within the normal range, less spleen enlargement and increased survival rates.
The researchers also noted that there were no off-target effects from the treatment, a finding that might suggest this method would be preferable over other gene editing techniques like CRISPR/Cas9, which can erroneously damage off-target DNA.
“CRISPR is much easier to use, which makes it ideal for laboratory research. But the off-site errors make it less useful for therapeutics,” said Ly. “The PNA technique is more ideal for therapeutics. It doesn’t cut the DNA, it just binds to it and repairs things that seem unusual. We looked at 50 million samples and couldn’t find one offsite error when we used our PNA gene editing technique.”
The researchers believe that their technique might be able to achieve even higher success rates if they can administer it multiple times during gestation. They also hope to see if their technique can be applied to other conditions .
The Latest on: Curing a genetic condition in utero
via Google News
The Latest on: Curing a genetic condition in utero
- Researchers identify link between ALS and accumulation of DNA-RNA hybrids in the genomeon January 13, 2021 at 5:12 am
Researchers from the University of Seville and the University of Pavia have identified a link between Amyotrophic Lateral Sclerosis (ALS) and the accumulation of DNA-RNA hybrids in the genome.
- Tessera Therapeutics scores $230M to ramp up 'gene writing' tech to cure diseaseon January 12, 2021 at 7:16 am
There’s a new kid on the block. Tessera Therapeutics is pioneering “gene writing,” a kind of genetic medicine it hopes will surmount the limitations of gene editing and gene therapy—and investors have ...
- Biotech startup Tessera takes in $230m to go after ‘gene writing’on January 12, 2021 at 5:36 am
The company is advancing a new technology it calls “gene writing,” entering the field of genetic medicine in which other companies are pursuing approaches such as gene editing and gene therapy.
- Woman has 12 operations in nine years to treat common condition with no cureon January 11, 2021 at 2:46 am
Sign up here! A 27-year-old woman has had 12 operations in the last nine years to help treat a painful condition with no cure. It might sound rare, and undoubtedly scary, but Anna Cooper is suffering ...
- I live in pain every day but everyone told me 'It's just your period'on January 9, 2021 at 9:00 pm
At 27 years old, Anna Cooper has already undergone 12 operations in the last nine years. Every day she is in some form of pain, managed by slow-release morphine, or liquid morphine when things are ...
- DNA Base Editing May Treat Progeria, Study in Mice Showson January 7, 2021 at 6:06 am
My good friend Sam Berns was born with a rare genetic condition that causes rapid premature aging. Though Sam passed away in his teens from complications of this condition, called ...
- CRISPR cures progeria in mice, raising hope for one-time therapy for a disease that causes rapid agingon January 6, 2021 at 12:31 pm
If the results are confirmed in human trials, “this has the feel of something that could be a true genetic cure with a single injection.” ...
- 'A cause for celebration': New gene editing tool offers promise of treating many genetic diseaseson January 6, 2021 at 11:39 am
A new study in the journal Nature demonstrates a tool that could fix single-letter genetic mistakes behind thousands of diseases, such as progeria.
- Local company tests potential of 'genetic scissors'on December 16, 2020 at 2:51 pm
WHEN YOU THINK OF CERTAIN GENETIC DISORDERS, IF WE C ISOLATE THE GENE THAT CAUSES IT, IT ALLOWS US TO START THINKING ABOUT WAYS TO REPAIR THAT GENE AND POTENTIALLY REVERSE AND CURE THE DISEASE.
- Gene-editing treatment shows promise for sickle cell diseaseon December 5, 2020 at 12:10 pm
Scientists are seeing promising early results from the first studies testing gene editing for painful, inherited blood disorders ... problem at its genetic roots. In the womb, fetuses make a ...
via Bing News